Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 261

1.

Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.

Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C, Gitelman SE, Greenbaum CJ, Gottlieb PA, Herold KC, Hessner MJ, Knip M, Jacobsen L, Krischer JP, Long SA, Lundgren M, McKinney EF, Morgan NG, Oram RA, Pastinen T, Peters MC, Petrelli A, Qian X, Redondo MJ, Roep BO, Schatz D, Skibinski D, Peakman M.

Diabetes Care. 2019 Nov 21. pii: dc190880. doi: 10.2337/dc19-0880. [Epub ahead of print]

PMID:
31753960
2.

Circulating β cell-specific CD8+ T cells restricted by high-risk HLA class I molecules show antigen experience in children with and at risk of type 1 diabetes.

Yeo L, Pujol-Autonell I, Baptista R, Eichmann M, Kronenberg-Versteeg D, Heck S, Dolton G, Sewell AK, Härkönen T, Mikk ML, Toppari J, Veijola R, Knip M, Ilonen J, Peakman M.

Clin Exp Immunol. 2019 Oct 29. doi: 10.1111/cei.13391. [Epub ahead of print]

PMID:
31660582
3.

Proinsulin peptide promotes autoimmune diabetes in a novel HLA-DR3-DQ2-transgenic murine model of spontaneous disease.

Verhagen J, Yusuf N, Smith EL, Whettlock EM, Naran K, Arif S, Peakman M.

Diabetologia. 2019 Dec;62(12):2252-2261. doi: 10.1007/s00125-019-04994-8. Epub 2019 Oct 14.

4.

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9.

5.

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.

Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group.

Diabetes. 2019 Jun;68(6):1267-1276. doi: 10.2337/db19-0057. Epub 2019 Apr 9.

6.

Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy.

Dul M, Nikolic T, Stefanidou M, McAteer MA, Williams P, Mous J, Roep BO, Kochba E, Levin Y, Peakman M, Wong FS, Dayan CM, Tatovic D, Coulman SA, Birchall JC; EE-ASI Consortium.

Int J Pharm. 2019 May 1;562:303-312. doi: 10.1016/j.ijpharm.2019.03.041. Epub 2019 Mar 22.

PMID:
30910633
7.

Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine.

Roep BO, Wheeler DCS, Peakman M.

Lancet Diabetes Endocrinol. 2019 Jan;7(1):65-74. doi: 10.1016/S2213-8587(18)30109-8. Epub 2018 Oct 24. Review.

PMID:
30528100
8.

The challenge of modulating β-cell autoimmunity in type 1 diabetes.

Atkinson MA, Roep BO, Posgai A, Wheeler DCS, Peakman M.

Lancet Diabetes Endocrinol. 2019 Jan;7(1):52-64. doi: 10.1016/S2213-8587(18)30112-8. Epub 2018 Oct 24. Review.

PMID:
30528099
9.

Proinsulin-mediated induction of type 1 diabetes in HLA-DR4-transgenic mice.

Verhagen J, Smith EL, Whettlock EM, Macintyre B, Peakman M.

Sci Rep. 2018 Sep 20;8(1):14106. doi: 10.1038/s41598-018-32546-4.

10.

Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes.

Triolo TM, Fouts A, Pyle L, Yu L, Gottlieb PA, Steck AK; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2019 Feb;42(2):192-199. doi: 10.2337/dc18-0288. Epub 2018 Jul 30.

PMID:
30061316
11.

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.

Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group.

Diabetes Care. 2018 Sep;41(9):1917-1925. doi: 10.2337/dc18-0494. Epub 2018 Jul 16.

12.

Optimized Peptide-MHC Multimer Protocols for Detection and Isolation of Autoimmune T-Cells.

Dolton G, Zervoudi E, Rius C, Wall A, Thomas HL, Fuller A, Yeo L, Legut M, Wheeler S, Attaf M, Chudakov DM, Choy E, Peakman M, Sewell AK.

Front Immunol. 2018 Jun 29;9:1378. doi: 10.3389/fimmu.2018.01378. eCollection 2018.

13.

A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk.

Redondo MJ, Geyer S, Steck AK, Sharp S, Wentworth JM, Weedon MN, Antinozzi P, Sosenko J, Atkinson M, Pugliese A, Oram RA; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2018 Sep;41(9):1887-1894. doi: 10.2337/dc18-0087. Epub 2018 Jul 12.

14.

In silico and ex vivo approaches indicate immune pressure on capsid and non-capsid regions of coxsackie B viruses in the human system.

Kundu R, Knight R, Dunga M, Peakman M.

PLoS One. 2018 Jun 20;13(6):e0199323. doi: 10.1371/journal.pone.0199323. eCollection 2018.

15.

Autoreactive T effector memory differentiation mirrors β cell function in type 1 diabetes.

Yeo L, Woodwyk A, Sood S, Lorenc A, Eichmann M, Pujol-Autonell I, Melchiotti R, Skowera A, Fidanis E, Dolton GM, Tungatt K, Sewell AK, Heck S, Saxena A, Beam CA, Peakman M.

J Clin Invest. 2018 Aug 1;128(8):3460-3474. doi: 10.1172/JCI120555. Epub 2018 Jul 16.

16.

Relationship between islet autoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohort.

Bravis V, Kaur A, Walkey HC, Godsland IF, Misra S, Bingley PJ, Williams AJK, Dunger DB, Dayan CM, Peakman M, Oliver NS, Johnston DG; ADDRESS-2 Management Committee, Patient Advocate Group and Investigators.

BMJ Open. 2018 Apr 4;8(4):e020904. doi: 10.1136/bmjopen-2017-020904.

17.

Peptide Immunotherapy for Type 1 Diabetes-Clinical Advances.

Smith EL, Peakman M.

Front Immunol. 2018 Feb 28;9:392. doi: 10.3389/fimmu.2018.00392. eCollection 2018. Review.

18.

Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations.

Rius C, Attaf M, Tungatt K, Bianchi V, Legut M, Bovay A, Donia M, Thor Straten P, Peakman M, Svane IM, Ott S, Connor T, Szomolay B, Dolton G, Sewell AK.

J Immunol. 2018 Apr 1;200(7):2263-2279. doi: 10.4049/jimmunol.1700242. Epub 2018 Feb 26.

19.

Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders.

Pollak TA, Rogers JP, Nagele RG, Peakman M, Stone JM, David AS, McGuire P.

Schizophr Bull. 2019 Jan 1;45(1):233-246. doi: 10.1093/schbul/sby021. Review.

20.

Molecular Pathways for Immune Recognition of Preproinsulin Signal Peptide in Type 1 Diabetes.

Kronenberg-Versteeg D, Eichmann M, Russell MA, de Ru A, Hehn B, Yusuf N, van Veelen PA, Richardson SJ, Morgan NG, Lemberg MK, Peakman M.

Diabetes. 2018 Apr;67(4):687-696. doi: 10.2337/db17-0021. Epub 2018 Jan 17.

Supplemental Content

Loading ...
Support Center